NASDAQ:SCNI Scinai Immunotherapeutics (SCNI) Stock Price, News & Analysis $0.51 +0.01 (+1.19%) As of 10:15 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Scinai Immunotherapeutics Stock (NASDAQ:SCNI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get SCNI alerts:Sign Up Key Stats Today's Range$0.51▼$0.5350-Day Range$0.46▼$0.8552-Week Range$0.45▼$6.18Volume10,063 shsAverage Volume2.28 million shsMarket Capitalization$1.81 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors. Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts. These partnerships support lead optimization, biomarker identification and the generation of preclinical efficacy and safety data in preparation for eventual clinical evaluation. Headquartered in the United States, Scinai Immunotherapeutics conducts its research and development activities primarily in North America while pursuing strategic alliances to extend its presence into European and Asian markets. The company remains focused on translating its scientific platform into robust therapeutic options, underpinned by rigorous preclinical validation and translational research initiatives.AI Generated. May Contain Errors. Read More Scinai Immunotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks10th Percentile Overall ScoreSCNI MarketRank™: Scinai Immunotherapeutics scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingScinai Immunotherapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageScinai Immunotherapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Scinai Immunotherapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Scinai Immunotherapeutics is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Scinai Immunotherapeutics is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioScinai Immunotherapeutics has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Scinai Immunotherapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.33% of the float of Scinai Immunotherapeutics has been sold short.Short Interest Ratio / Days to CoverScinai Immunotherapeutics has a short interest ratio ("days to cover") of 0.03, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Scinai Immunotherapeutics has recently increased by 780.25%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldScinai Immunotherapeutics does not currently pay a dividend.Dividend GrowthScinai Immunotherapeutics does not have a long track record of dividend growth. News and Social Media2.2 / 5News Sentiment0.54 News SentimentScinai Immunotherapeutics has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Scinai Immunotherapeutics this week, compared to 0 articles on an average week. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Scinai Immunotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders60.90% of the stock of Scinai Immunotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions58.41% of the stock of Scinai Immunotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Scinai Immunotherapeutics' insider trading history. Receive SCNI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Scinai Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SCNI Stock News HeadlinesScinai Immunotherapeutics (NASDAQ:SCNI) Shares Down 9.8% - What's Next?May 12 at 2:16 AM | americanbankingnews.comScinai Immunotherapeutics Announces $2.61 Million Private Placement FinancingApril 24, 2026 | prnewswire.comIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.May 14 at 1:00 AM | American Alternative (Ad)Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 PrioritiesApril 6, 2026 | prnewswire.comScinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm CollaborationApril 1, 2026 | prnewswire.comScinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026March 19, 2026 | prnewswire.comScinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid PriceMarch 16, 2026 | prnewswire.comScinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of ConceptMarch 2, 2026 | prnewswire.comSee More Headlines SCNI Stock Analysis - Frequently Asked Questions How have SCNI shares performed this year? Scinai Immunotherapeutics' stock was trading at $0.7121 at the beginning of the year. Since then, SCNI shares have decreased by 28.9% and is now trading at $0.5060. How were Scinai Immunotherapeutics' earnings last quarter? Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) announced its earnings results on Wednesday, April, 1st. The company reported $3.80 EPS for the quarter. The business earned $0.27 million during the quarter. When did Scinai Immunotherapeutics' stock split? Scinai Immunotherapeutics's stock reverse split before market open on Tuesday, May 21st 2024.The 1-10 reverse split was announced on Tuesday, May 21st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 21st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Scinai Immunotherapeutics IPO? Scinai Immunotherapeutics (SCNI) raised $14 million in an initial public offering on Friday, May 1st 2015. The company issued 1,910,000 shares at $7.32 per share. How do I buy shares of Scinai Immunotherapeutics? Shares of SCNI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Scinai Immunotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Scinai Immunotherapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET), AppLovin (APP), e.l.f. Beauty (ELF) and Disc Medicine (IRON). Company Calendar Last Earnings4/01/2026Today5/14/2026Next Earnings (Estimated)7/07/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 SCNI's financial health is in the Red zone, according to TradeSmith. SCNI has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SCNI Previous SymbolNASDAQ:SCNI CIK1611747 Webwww.scinai.com Phone972-8-930-2529Fax972-8930-2531Employees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.12 Current Ratio1.30 Quick Ratio1.30 Sales & Book Value Annual Sales$1.31 million Price / Sales1.38 Cash FlowN/A Price / Cash FlowN/A Book Value$0.78 per share Price / Book0.66Miscellaneous Outstanding Shares3,536,000Free Float1,383,000Market Cap$1.81 million OptionableNot Optionable Beta2.19 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2026. Learn which stocks have the most short interest and how to trade them. Click the link to see which companies made the list.Get This Free Report This page (NASDAQ:SCNI) was last updated on 5/14/2026 by MarketBeat.com Staff. From Our PartnersMicroscopic Footage Shows Immune Cells Attacking CancerEarly human trial data from one NASDAQ-listed biotech showed up to a 63.7% reduction in cancer burden using it...Market Tactic | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredThe US sanctioned itself out of world reserve status…Russia and Iran are both bypassing the US petrodollar - settling oil trades in alternative currencies while ce...Golden Portfolio | SponsoredPeptide Company Lands Exclusive MMA Wellness PartnershipA publicly traded peptide company just signed an exclusive partnership with a NYSE-listed MMA media platform t...The Tomorrow Investor | SponsoredCollect $1,170 a month from silverI've Rarely Seen This With Silver This combination - 20% dividends + 68% share appreciation - never happens...Investors Alley | SponsoredYour temporary download link is expiringBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scinai Immunotherapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Scinai Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
